Revenue: €12.0m (up 21% from FY 2023). Net loss: €19.4m (loss narrowed by 4.7% from FY 2023). €0.42 loss per share (improved from €0.44 loss in FY 2023). Revenue exceeded analyst estimates ...

Revenue: €12.0m (up 21% from FY 2023). Net loss: €19.4m (loss narrowed by 4.7% from FY 2023). €0.42 loss per share (improved from €0.44 loss in FY 2023). Revenue exceeded analyst estimates by 11%.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.

This information can also be found on the Investors section of the Innate Pharma website ... anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral ...

Purdue Pharma filed a new bankruptcy plan on Tuesday ... The cash value of the plan assumes full creditor participation. Purdue said it expects widespread creditor support for the deal.

Purdue Pharma LP has filed a new Chapter 11 plan with the US Bankruptcy Court for the Southern District of New York, pledging it will give creditors including US states and other parties more than ...

Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Purdue Pharma asked a bankruptcy judge late Tuesday to consider the latest ... Under the new version, plaintiffs will have to opt ...